Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA...
Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA...
Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA 2024 Conference
Penumbra將在VIVA 2024年會議上展示新的晚期數據，顯示接受計算機輔助抽真空血栓切除技術治療肺栓塞的患者，與其他治療期權相比，住院時間更短，併發症更少。
- Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference
- Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system
- 數據首次在Vascular Interventional Advances（VIVA）2024年會議上展示。
- 研究結果進一步強調了計算機輔助抽真空血栓切除對患者和整體衛生系統的臨床、衛生經濟和成本效益。
ALAMEDA, Calif., Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.
加利福尼亞州阿拉米達，2024年11月5日/ PRNewswire / - 美國Penumbra, Inc.（紐交所：PEN），全球領先的血栓切除公司，宣佈新數據顯示，接受Penumbra的計算機輔助抽真空血栓切除（CAVT）技術治療中危肺栓塞（PE）的患者，住院時間更短，術後住院時間更短，併發症更少，與其他治療期權相比。此外，在CAVT中住院死亡率低，各治療期權之間沒有顯著差異。此項晚期研究於Vascular Interventional Advances（VIVA）2024年會議上展示。
